Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775966 | 0.88 | MMP12 (0.60) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL29793805 | 0.88 | MMP12 (0.60) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24346161 | 0.88 | MMP12 (0.60) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24999115 | 0.88 | MMP12 (0.60) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3703323 | 0.88 | MMP12 (0.60) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8001478 | 0.87 | MMP12 (0.51) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8195980 | 0.85 | ACLY (0.58) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4134290 | 0.84 | MMP12 (0.56) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL18500395 | 0.83 | PARP1 (0.62) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL18598584 | 0.83 | PARP1 (0.58) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2024061853-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024020068-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023247666-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-4186896-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008121592-A2 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | WO | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | MMP12 2523/4885PARP1 399/4885ALDH1A1 901/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | MMP12 926/4885PARP1 3792/4885ALDH1A1 2716/4885 |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | MMP12 2310/4885PARP1 2117/4885ALDH1A1 3801/4885 |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | REN, GRIK5, CAT | MMP12 1850/4885PARP1 3448/4885ALDH1A1 506/4885 |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | MMP12 4599/4885PARP1 644/4885ALDH1A1 3843/4885 |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | MMP12 1080/4885PARP1 2796/4885ALDH1A1 1691/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | MMP12 3455/4885PARP1 703/4885ALDH1A1 72/4885 |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | MMP12 2535/4885PARP1 1575/4885ALDH1A1 118/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | MMP12 3295/4885PARP1 3367/4885ALDH1A1 4026/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | MMP12 574/4885PARP1 2505/4885ALDH1A1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.